At the end of the trading day, Innovent Bio (01801) jumped more than 6%, as of press time, the increase was 6.11%, at HKD 39.05, with a turnover of HKD 0.211 billion.
According to the WiseNews app, Innovent Bio (01801) rose more than 6% at the end of the trading day. As of press time, the stock rose 6.11%, to HKD 39.05, with a turnover of HKD 0.211 billion.
China Merchants Securities pointed out that Innovent Bio, as a leading biopharmaceutical company in China, continues to improve its operational efficiency and maintains consistently high clinical advancement efficiency. At the same time, its self-developed pipeline products are gradually being listed, and early-stage pipeline includes varieties with potential for overseas expansion. The bank believes that Innovent Bio is expected to enter an accelerated growth phase.
Nomura previously published a research report forecasting the sales of Innovent Bio's core product PD-1 antibody sintilimab Tyvyt for lung cancer in the next two years, increasing the prediction from RMB 2.9 billion and RMB 3 billion to RMB 3.2 billion and RMB 3.4 billion respectively. Accordingly, the company's net loss forecast for this year has been narrowed down to RMB 0.511 billion, and it is expected to turn losses in 2025. The net profit forecast for next year has been raised by 12% to RMB 0.202 billion.